Claims
- 1. A pharmaceutical composition containing a therapeutically effective amount of a compound of the formula ##STR35## wherein R denotes an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic or araliphatic radical having 2 or more carbon atoms, and wherein one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen or an aliphatic, cycloaliphatic, araliphatic or aromatic radical, another one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen or, wherein R.sup.1 and R.sup.2 are hydroxy, and the remaining one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen, or wherein R denotes methyl, R.sub.1 denotes hydrogen or hydroxy, R.sub.2 denotes an aromatic radical and R.sub.3 represents hydrogen, or of a pharmaceutically acceptable salt thereof in admixture to a conventional pharmaceutical carrier system with the exception of aqueous or water-containing solutions of compounds of the formula I, wherein R is .alpha.,.alpha.-C.sub.1 -C.sub.4 alkoxy-C.sub.1 -C.sub.4 alkyl, one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.8 -cycloalkyl, phenyl, C.sub.7 -C.sub.10 phenylalkyl, phenyl substituted by halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy and/or trifluoromethyl or C.sub.7 -C.sub.10 phenylalkyl substituted by halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy and/or trifluoromethyl and the other two of R.sup.1, R.sup.2 and R.sup.3 are hydrogen.
- 2. A pharmaceutical composition as claimed in claim 1, containing, as the active ingredient a compound of the formula I, wherein R has 2 or more carbon atoms and denotes alkyl, alkenyl, alkynyl, alkyl or alkenyl substituted by halogen and/or hydroxy, alkyl being interrupted by one or two mutually spaced atoms selected from oxygen and sulfur, alkyl being interrupted by one or two mutually spaced atoms selected from oxygen and sulfur and substituted by halogen and/or hydroxy, cycloalkyl, cycloalkyl substituted by hydroxy, cycloalkyl being interrupted by one or two mutually spaced atoms selected from oxygen and sulfur, cycloalkyl-lower alkyl, cycloalkyl-lower alkyl substituted in the cycloalkyl moiety by hydroxy or lower alkylthio and/or in the alkylene moiety by hydroxy, cycloalkyl-lower alkyl being interrupted by one or two mutually spaced atoms selected from oxygen and sulfur in the cycloalkyl moiety, phenyl-or naphthyl-lower alkyl or phenyl- or naphthyl-lower alkyl ring-substituted by halogen, lower alkyl, lower alkoxy and/or trifluoromethyl and/or chain-substituted by hydroxy, and wherein one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen, lower alkyl, cycloalkyl, phenyl or naphthyl, phenyl or naphthyl substituted by halogen, lower alkyl, lower alkoxy and/or trifluoromethyl, phenyl-lower alkyl or phenyl lower alkyl substituted in the phenyl moiety by halogen, lower alkyl, lower alkoxy and/or trifluoromethyl, another one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen or, in the case of R.sup.1 and R.sup.2 is hydroxy and the remaining one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen, or a pharmaceutically acceptable salt thereof.
- 3. A pharmaceutical composition as claimed in claim 1, containing, as the active ingredient a compound of the formula I, wherein R has 2 or more carbon atoms and is lower alkyl, lower alkenyl, lower alkynyl, a cycloalkyl, hydroxycycloalkyl, cycloalkyl-lower alkyl, cycloalkyl-(hydroxy)lower alkyl or lower alkylthiocycloalkyl-(hydroxy)lower alkyl group having 3 to 6 ring carbon atoms, mono- or dihydroxy-lower alkyl, hydroxy-lower alkenyl, mono-, di- or polyhalogeno-lower alkyl, mono-, di- or polyhalogeno-lower alkenyl, mono-, di- or polyhalogeno-(hydroxy)lower alkyl, mono-, di- or polyhalogeno-(hydroxy)lower alkenyl, lower alkoxy-lower alkyl, lower alkylthio-lower alkyl, lower alkanesulfinyl-lower alkyl, lower alkanesulfonyl-lower alkyl, di-lower alkoxy-lower alkyl, di-lower alkylthio-lower alkyl, lower alkoxy-(hydroxy)lower alkyl, lower alkoxy-(halogeno)lower alkyl, phenyl-lower alkyl, phenyl-lower hydroxyalkyl, phenyl-lower alkyl mono- or disubstituted in the phenyl moiety by halogen, lower alkyl or phenyl-lower hydroxyalkyl, lower alkoxy and/or trifluoromethyl, naphthyl-lower alkyl, oxa- or thiacycloalkyl having 2 to 6 ring carbon atoms, or dioxa-, oxathia- or dithiacycloalkyl having 3 to 5 ring carbon atoms, and wherein one of R.sup.1, R.sup.2, R.sup.3 represents hydrogen, lower alkyl, cycloalkyl having 3 to 6 ring carbon atoms, phenyl, phenyl mono- or disubstituted by halogen, lower alkyl, lower alkoxy and/or trifluoromethyl, phenyl-lower alkyl or phenyl-lower alkyl mono- or disubstituted by halogen, lower alkyl, lower alkoxy and/or trifluoromethyl, another one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen or, in the case of R.sup.1 and R.sup.2, is hydroxy; and the remaining one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen, or a pharmaceutically acceptable salt thereof for use for the treatment of the human or animal body.
- 4. A pharmaceutical composition as claimed in claim 1, containing, as the active ingredient a compound of the formula I, wherein R is C.sub.2 -C.sub.12 -alkyl, C.sub.2 -C.sub.7 -alkenyl, C.sub.2 -C.sub.7 -alkynyl, mono- or dihydroxy-C.sub.2 -C.sub.7 -alkyl, mono-, di- or trihalogeno-.alpha.-hydroxy-C.sub.3 -C.sub.7 -alkyl, .alpha.-saturated mono-, di- or trihalogeno-.alpha.-hydroxy-C.sub.3 -C.sub.7 -alkenyl, C.sub.1 -C.sub.4 -alkoxy-C.sub.1 -C.sub.4 -alkyl, di-C.sub.1 -C.sub.4 -alkoxy-C.sub.1 -C.sub.4 -alkyl, .alpha.-hydroxy-C.sub.3 -C.sub.6 -cycloalkyl, C.sub.3 -C.sub.6 -cycloalkyl-C.sub.1 -C.sub.4 -alkyl, C.sub.3 -C.sub.6 -cycloalkyl-.alpha.-hydroxy-C.sub.1 -C.sub.3 -alkyl, or (2-C.sub.1 -C.sub.4 -alkylthiocycloalkyl)-.alpha.-hydroxy-C.sub.1 -C.sub.4 -alkyl, R.sup.2 represents hydrogen, hydroxy, C.sub.1 -C.sub.4 -alkyl, phenyl or phenyl substituted by halogen, such as chloro, or C.sub.1 -C.sub.4 -alkyl and R.sup.1 and R.sup.3 are hydrogen or one of R.sup.1 and R.sup.2 denotes hydroxy and the other one as well as R.sup.3 represents hydrogen, or a pharmaceutically acceptable salt thereof.
- 5. A pharmaceutical composition as claimed in claim 1, containing, as the active ingredient a compound of the formula I, wherein R denotes C.sub.2 -C.sub.7 -alkyl, .alpha.-saturated C.sub.3 -C.sub.7 -alkenyl, .alpha.-saturated C.sub.3 -C.sub.7 -alkynyl, .alpha.-, .beta.-, .gamma.- or .delta.-hydroxy-C.sub.2 -C.sub.7 -alkyl, .alpha.,.beta.-dihydroxy-C.sub.2 -C.sub.7 -alkyl, mono-, di- or trifluoro-.alpha.-hydroxy-C.sub.3 -C.sub.7 -alkyl, .alpha.-saturated mono-, di- or trifluoro-.alpha.-hydroxy-C.sub.3 -C.sub.7 -alkenyl, C.sub.1 -C.sub.4 -alkoxy-C.sub.1 -C.sub.4 -alkyl, C.sub.3 -C.sub.6 -cycloalkyl-C.sub.1 -C.sub.4 -alkyl, .alpha.-hydroxy-C.sub.3 -C.sub.6 -cycloalkyl or C.sub.3 -C.sub.6 -cycloalkyl-.alpha.-hydroxy-C.sub.1 -C.sub.4 -alkyl and R.sup.1, R.sup.2 and R.sup.3 represent hydrogen, or a pharmaceutically acceptable salt thereof.
- 6. A pharmaceutical composition as claimed in claim 1, containing, as the active ingredient a compound of the formula I, wherein R denotes di-C.sub.1 -C.sub.4 -alkoxy-C.sub.1 -C.sub.4 -alkyl, and R.sup.1, R.sup.2 and R.sup.3 represent hydrogen, or a pharmaceutically acceptable salt thereof.
- 7. A pharmaceutical composition according to claim 1 containing a therapeutically effective amount of a compound of the formula I, wherein R denotes an aliphatic, cycloaliphatic, cycloaliphatic-aliphatic or araliphatic radical having 2 or more carbon atoms, one of R.sub.1, R.sub.2 and R.sub.3 represents hydrogen or an aliphatic, araliphatic or aromatic radical, another one of R.sub.1, R.sub.2 and R.sub.3 is hydrogen or, in the case of R.sub.1 or R.sub.2, is hydroxy and the remaining one of R.sub.1, R.sub.2 and R.sub.3 is hydrogen, or wherein R denotes methyl, R.sub.1 denotes hydrogen or hydroxy, R.sub.2 denotes an aromatic radical and R.sub.3 represents hydrogen, or a pharmaceutically acceptable salt thereof, provided that
- (a) R is different from .alpha.,.alpha.-di-C.sub.1 -C.sub.4 alkoxy-C.sub.1 -C.sub.4 alkyl, if one of R.sup.1, R.sup.2 and R.sup.3 is hydrogen, C.sub.1 -C.sub.8 alkyl, C.sub.3 -C.sub.7 cycloalkyl, phenyl, C.sub.7 -C.sub.10 phenylalkyl or a phenyl or C.sub.1 -C.sub.10 phenylalkyl radical substituted by halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy and/or trifluoromethyl and the other two of R.sup.1, R.sup.2 and R.sup.3 are hydrogen;
- (b) R is different from ethyl if R.sup.2 is hydroxy and R.sup.1 and R.sup.3 are hydrogen; and
- (c) salts of compounds of the formula I, wherein R is an unsubstituted aliphatic, cycloaliphatic or araliphatic hydrocarbon radical, R.sup.2 is hydrogen or alkyl and R.sup.1 and R.sup.3 are hydrogen, are different from alkali metal or ammonium salts.
Priority Claims (1)
Number |
Date |
Country |
Kind |
8728483 |
Dec 1987 |
GB2 |
|
Parent Case Info
This is a continuation-in-part application of our co-pending patent application Ser. No. 484,716, filed Feb. 26, 1990 which is a continuation-in-part of our co-pending patent application Ser. No. 378,887, filed July 12, 1989 which in turn is a continuation-in-part of our previous patent application Ser. No. 275,882, filed Nov. 25, 1988 now abandoned.
US Referenced Citations (4)
Foreign Referenced Citations (3)
Number |
Date |
Country |
181833 |
May 1986 |
EPX |
356128 |
Feb 1990 |
EPX |
1351503 |
May 1974 |
GBX |
Non-Patent Literature Citations (3)
Entry |
Brit. J. Pharmacology, vol. 101, pp. 949-957 (1990). |
Phosphorus and Sulfur, vol. 18, pp. 353-356 (1983). |
Chem. Abstracts, 97:72585v (1982). |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
484716 |
Feb 1990 |
|
Parent |
378887 |
Jul 1989 |
|
Parent |
275882 |
Nov 1988 |
|